Lazela

Ranolazine, the active ingredient in Lazela, is a antianginal agent presented as an oral dosage form for oral use. It treats chronic stable angina in adults, helping to reduce the frequency of chest pain episodes and improve exercise tolerance.

GNH USA supplies Lazela as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lazela is an antianginal medication indicated for conditions affecting myocardial oxygen supply and demand.

Chronic stable angina: reduces the frequency of angina attacks and improves exercise capacity. Ischemic heart disease: enhances myocardial perfusion during physical exertion. Refractory angina: may be added as adjunct therapy when standard antianginals are insufficient.

Lazela may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Nausea - Fatigue - Palpitations

Serious or Rare Side Effects: - QT interval prolongation - Life‑threatening ventricular arrhythmias - Severe hypotension - Hepatic dysfunction - Pulmonary edema - Allergic skin reactions such as Stevens‑Johnson syndrome

Before initiating Lazela, several safety considerations should be reviewed.

Monitor ECG: assess QT interval baseline and during therapy. Assess renal function: dose adjustment may be required in renal impairment. Evaluate hepatic status: avoid in severe hepatic dysfunction. Avoid in patients with known QT prolongation or congenital long‑QT syndrome. Review concomitant medications: especially other QT‑prolonging agents. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Ranolazine interacts with several drug classes; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ranolazine exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Other QT‑prolonging antiarrhythmics (e.g., dofetilide, sotalol): risk of severe arrhythmias.

Moderate Interactions (Monitor Closely): - Digoxin: may increase serum digoxin concentrations. - Warfarin: potential alteration of anticoagulant effect, requiring INR monitoring. - Calcium channel blockers (e.g., diltiazem, verapamil): may modestly raise ranolazine levels.